Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecules and other candidates for immune-inflammatory conditions. Its pipeline includes Bosakitug (ATI-045), which is being studied in Phase 2 trials for several respiratory and dermatologic indications; ATI-2138, a Phase 2a investigational inhibitor being evaluated for T cell-mediated autoimmune diseases; ATI-052, a bispecific antibody in early-stage testing; ATI-9494, an oral investigational inhibitor designed to affect T cell biology across multiple diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor under development for atopic dermatitis and related skin disorders. The company was incorporated in 2012 and is based in Wayne, Pennsylvania. Aclaris Therapeutics common stock trades on the NASDAQ under the symbol ACRS.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACRS
|
—
|
—
|
—
|
$10
|
79.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-11.2x
|
5.4x
|
92.9x
|
777.9 M
|
588.4 M
|
0.3%
|
81.0%
|
0.8
|
—
|
75.1%
|
